Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life Technologies Timely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT as Actinium advances toward key data readouts and expanded clinical trials in 2H:2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience.

PRNewsWire • Jun 1, 2026

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.

Business Wire • May 11, 2026

Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.

GlobeNewsWire • Apr 7, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company.

PRNewsWire • Apr 1, 2026

LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal

Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.

Zacks Investment Research • Apr 1, 2026

Eli Lilly to buy Centessa Pharma in $6.3 billion deal

Eli ​Lilly ‌said ​on ​Tuesday ⁠it ​would ​buy Centessa ​Pharmaceuticals ​in a ‌deal ⁠worth ​about $6.3 ​billion ⁠to ​advance ​treatments ⁠for ⁠sleep-wake ​disorders.

Reuters • Mar 31, 2026

Why Centessa Stock Soared Today

Centessa possesses a promising sleep medicine pipeline. The clinical-stage company's experimental therapies have blockbuster potential.

The Motley Fool • Apr 1, 2026

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.

CNBC • Mar 31, 2026

CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Centessa Pharmaceuticals plc (NASDAQ: CNTA) to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones.Halper Sadeh encourages Centessa shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary.

Business Wire • Mar 31, 2026

Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket

Eli Lilly said Tuesday it would buy sleep-wake disorders drugmaker Centessa Pharmaceuticals for up to $7.8 billion.

Investors Business Daily • Mar 31, 2026